bismuth has been researched along with astatine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Neirinckx, RD; Smit, JA | 1 |
| Chin, LM; Humm, JL | 1 |
| Bigner, DD; Zalutsky, MR | 1 |
| Larsen, RH; Wieland, BW; Zalutsky, MR | 1 |
| Vaidyanathan, G; Zalutsky, MR | 1 |
| Beitzel, MP; Eckelman, WC; Gansow, OA; Plascjak, P; Schwarz, UP; Waldmann, TA | 1 |
| Allen, BJ | 1 |
| Charlton, DE | 1 |
| Henriksen, G; Larsen, RH; Messelt, S; Olsen, E | 1 |
| Bäck, T; Jensen, HJ; Lindegren, S | 1 |
| Imam, SK | 1 |
| Carrasquillo, JA; Dadachova, E; Eckelman, WC; Garmestani, K; Paik, CH; Park, LS; Waldmann, TA; Wong, KJ; Yao, Z; Yordanov, A | 1 |
| Akabani, G; Kennel, SJ; Zalutsky, MR | 1 |
| Bacher, JD; Brechbiel, MW; Decker, J; Eckelman, WC; Flynn, M; Gansow, OA; Garmestani, K; Goldman, CK; Jackson-White, T; MacLin, M; McGee, EC; Phillip, CM; Schwartz, UP; Waldmann, TA; Wesley, JN; Wu, C; Yordanov, AT | 1 |
| Basu, S; Lahiri, S; Nayak, D; Ramaswami, A; Roy, K | 1 |
| Pozzi, OR; Zalutsky, MR | 1 |
| Brechbiel, MW; Chyan, MK; Hamlin, DK; Wilbur, DS | 1 |
| Lucignani, G | 1 |
| Fisher, DR; Hamlin, DK; Kenoyer, AL; Nakamae, H; Pagel, JM; Press, OW; Sandmaier, BM; Santos, EB; Storb, R; Thakar, MS; Wilbur, DS | 1 |
| Akudugu, JM; Domogauer, JD; Howell, RW; Khullar, A; Pasternack, JB | 1 |
| Fukada, M; Hasegawa, S; Minegishi, K; Nagatsu, K; Suzuki, H; Zhang, MR | 1 |
| Al-Ramady, AM; Nafee, SS; Shaheen, SA | 1 |
| Ferrier, MG; Radchenko, V | 1 |
| Dizdarevic, S; McCready, R; Vinjamuri, S | 1 |
7 review(s) available for bismuth and astatine
| Article | Year |
|---|---|
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
Topics: Alpha Particles; Antibodies, Monoclonal; Astatine; Bismuth; Female; Half-Life; Humans; Immunoconjugates; Linear Energy Transfer; Lymphoma; Meningitis; Neoplasm Metastasis; Ovarian Neoplasms; Radioimmunotherapy; Radioisotopes | 1996 |
Targeted therapy using alpha emitters.
Topics: Alpha Particles; Antibodies, Monoclonal; Astatine; Bismuth; Cyclotrons; Humans; Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy | 1996 |
Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
Topics: Alpha Particles; Animals; Astatine; Bismuth; Humans; Immunoconjugates; Mice; Neoplasm Metastasis; Neoplasms; Radioisotopes; Terbium; Tumor Cells, Cultured | 1999 |
Advancements in cancer therapy with alpha-emitters: a review.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal; Astatine; Beta Particles; Bismuth; Cell Death; Energy Transfer; Fermium; Humans; Immunoconjugates; Neoplasms; Radioisotopes; Radium; Relative Biological Effectiveness; Terbium | 2001 |
Radioimmunotherapy with alpha-particle emitting radionuclides.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal; Astatine; Bismuth; Humans; Isotopes; Neoplasms; Practice Patterns, Physicians'; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Treatment Outcome | 2004 |
An Appendix of Radionuclides Used in Targeted Alpha Therapy.
Topics: Actinium; Alpha Particles; Astatine; Bismuth; Humans; Neoplasms; Radioisotopes; Radiotherapy; Radium; Thorium | 2019 |
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Topics: Actinium; Astatine; Bismuth; Bone Neoplasms; Humans; Lead Radioisotopes; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Thorium | 2020 |
17 other study(ies) available for bismuth and astatine
| Article | Year |
|---|---|
Separation of astatine-211 from bismuth metal.
Topics: Astatine; Bismuth; Ethers; Methods | 1973 |
A model of cell inactivation by alpha-particle internal emitters.
Topics: Alpha Particles; Astatine; Bismuth; Cell Survival; Computer Simulation; Dose-Response Relationship, Radiation; Models, Biological; Monte Carlo Method; Radioimmunodetection; Radioimmunotherapy; Radioisotopes | 1993 |
Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.
Topics: Astatine; Bismuth; Cyclotrons; Evaluation Studies as Topic; Half-Life; Radiochemistry; Radioisotopes | 1996 |
Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets.
Topics: Astatine; Bismuth; Chromatography, High Pressure Liquid; Cyclotrons; Drug Stability; Humans; Isotope Labeling; Radioisotopes; Radiopharmaceuticals; Receptors, Interleukin-2 | 1998 |
Radiation effects in spheroids of cells exposed to alpha emitters.
Topics: Alpha Particles; Animals; Astatine; Bismuth; Cell Count; Cell Survival; Humans; Models, Biological; Monte Carlo Method; Radioisotopes; Spheroids, Cellular | 2000 |
Optimisation of cyclotron production parameters for the 209Bi(alpha, 2n) 211At reaction related to biomedical use of 211At.
Topics: Astatine; Bismuth; Cyclotrons; Polonium; Radioisotopes; Radiopharmaceuticals | 2001 |
Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields.
Topics: Astatine; Bismuth; Half-Life; Radiochemistry; Radioisotopes | 2001 |
Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
Topics: Alpha Particles; Antibodies, Monoclonal; Astatine; Bismuth; CD5 Antigens; Humans; Immunoconjugates; Indium Radioisotopes; Iodine Radioisotopes; Lead Radioisotopes; Radioisotopes; Tumor Cells, Cultured | 2001 |
Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Topics: Alpha Particles; Animals; Astatine; Bismuth; Cell Survival; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Radioimmunotherapy; Radioisotopes; Radiometry; Radiotherapy Dosage; Tumor Cells, Cultured | 2003 |
Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
Topics: Animals; Antibodies, Monoclonal; Astatine; Bismuth; Female; Graft Rejection; Graft Survival; Macaca fascicularis; Mice; Mice, Nude; Protein Subunits; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Interleukin-2; Treatment Outcome | 2004 |
Incorporation of thiosemicarbazide in Amberlite IRC-50 for separation of astatine from alpha-irradiated bismuth oxide.
Topics: Astatine; Bismuth; Radiotherapy; Resins, Synthetic; Semicarbazides | 2004 |
Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
Topics: Alpha Particles; Animals; Astatine; Bismuth; Drug Carriers; Mice; Mice, Nude; Radioisotopes; Recombinant Proteins; Streptavidin | 2008 |
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Astatine; Bismuth; Brain Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Ovarian Neoplasms; Radioimmunotherapy; Radioisotopes | 2008 |
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Astatine; Bismuth; Female; Immunotoxins; Isotope Labeling; Kidney Diseases; Leukocyte Common Antigens; Liver Diseases; Mice; Mice, Inbred BALB C; Radiation Injuries, Experimental; Radioimmunotherapy; Radioisotopes; Rats; Tissue Distribution | 2009 |
The advantage of antibody cocktails for targeted alpha therapy depends on specific activity.
Topics: Actinium; Algorithms; Alpha Particles; Antibodies; Astatine; Bismuth; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Combinations; Female; Humans; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals | 2014 |
Production of (211)At by a vertical beam irradiation method.
Topics: Astatine; Bismuth; Heavy Ions; Isotope Labeling; Radiopharmaceuticals | 2014 |
Nuclear Data Evaluation for Mass Chain A=217:Odd-Proton Nuclei.
Topics: Actinium; Alpha Particles; Astatine; Bismuth; Electrons; Francium; Gamma Rays; Half-Life; Probability; Protactinium; Protons; Radioisotopes; Synchrotrons; Thallium | 2016 |